Athersys, Inc. (ATHXQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Mar 6, 2026, 9:30 AM EST
Athersys Company Description
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area.
Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions.
The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7.
It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.
Athersys, Inc.
| Country | United States |
| Founded | 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
Contact Details
Address: 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 United States | |
| Phone | 216 431 9900 |
| Website | athersys.com |
Stock Details
| Ticker Symbol | ATHXQ |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Z. Kasey Rosado | Interim Chief Financial Officer and Director |
| Dr. Senthil Ranganathan Ph.D. | Vice President of Technical Operations |
| David Russ M.B.A. | Vice President of Supply Chain, Finance and Administration |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Executive Vice President and Head of Global Regulatory Affairs |
| Dr. Robert Mays Ph.D. | Executive Vice President, Head of Regenerative Medicine and Neuroscience Programs |
| Rakesh Ramachandran MS | Head of Information Technology and Communications and Vice President |
| Dr. Sarah Busch Ph.D. | Vice President of Regenerative Medicine and Head of Business Development |
| Ellen Gurley | Manager of Corporate Communications and Investor Relations |